Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-12-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by shareholders holding more than 5% of the company's stock. It details the number of shares pledged, the proportion of total shares, and the financial implications of these pledges. There is no financial statement, earnings data, or management discussion present. The document is a regulatory disclosure about share pledging, which is a capital/financing activity related to the company's shareholders. It is not an annual report, earnings release, or any other detailed financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 2839 characters, which is consistent with an announcement rather than a full report.
2024-12-30 Chinese
关于持股5%以上股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a shareholder holding more than 5% of the company's shares. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, and other related information. There is no financial statement, earnings data, or management discussion. The document is a regulatory disclosure about share pledging, which fits the category of a Major Shareholding Notification or related shareholder information. Given the focus on share pledging by a significant shareholder, the most appropriate classification is Major Shareholding Notification (MRQ). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS. Therefore, the classification is MRQ with high confidence.
2024-11-15 Chinese
关于2023年限制性股票激励计划第一个归属期归属结果暨股份上市的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the first vesting period results of its 2023 restricted stock incentive plan. It includes information about the number of shares vested, the vesting conditions, approval procedures, adjustments to the plan, legal opinions, and the impact on share capital. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is also not a call transcript, earnings release, or a regulatory filing of a different nature. The content focuses on the stock incentive plan's vesting results and related disclosures, which fits the category of a Capital/Financing Update (CAP) because it deals with equity incentives, share issuance, and related capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-11-12 Chinese
关于全资子公司取得换发的《药品生产许可证》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the issuance of a renewed pharmaceutical production license for a wholly-owned subsidiary. It details the license information, changes in production authorization, and the expected impact on the company's operations and market. The document is relatively short (1546 characters) and does not contain financial statements, detailed financial data, or regulatory certifications. It is an official announcement about a regulatory approval related to production capabilities rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-31 Chinese
第三届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's third board of directors' fifth meeting, including approval of the 2024 third quarter report, stock incentive plan adjustments, and other board decisions. It is titled as a "董事会会议决议公告" (Board Meeting Resolution Announcement) and contains voting results and references to related disclosures on a public information website. The document does not contain the full financial report or detailed financial data itself but rather announces board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (1881 characters), and it is not a full report or transcript but a formal board meeting resolution announcement.
2024-10-23 Chinese
关于作废部分已授予但尚未归属的第二类限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Enwei Pharmaceutical Co., Ltd. regarding the cancellation of a portion of previously granted but unvested restricted shares under the 2023 restricted stock incentive plan. It details board and supervisory committee meeting approvals, legal opinions, and the impact of the cancellation on the company. The content focuses on corporate governance and share incentive plan adjustments rather than financial results or earnings. The document length is about 3,063 characters, which is relatively short and primarily an announcement of a corporate action related to share incentives. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about share incentive plan adjustments and cancellations, not a full report or financial statement.
2024-10-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.